Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21605177 | 0.79 | NOTUM (0.33) | KDM4EGAAMGLLNOTUMALDH1A1 | |
| Hydrochloric Acid SCHEMBL21598436 | 0.78 | NPSR1 (0.34) | KDM4EGAAMGLLNOTUMALDH1A1 | |
| SCHEMBL12459925 | 0.77 | GAA (0.40) | KDM4EGAATRPV1ALDH1A1MAPT | |
| SCHEMBL8312389 | 0.77 | NOTUM (0.33) | KDM4EGAAMGLLNOTUMALDH1A1 | |
| SCHEMBL19472658 | 0.73 | TRPV1 (0.47) | KDM4ETRPV1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL12905324 | 0.72 | ALDH1A1 (0.45) | KDM4EGAANOTUMALDH1A1L3MBTL1 | |
| SCHEMBL21598438 | 0.71 | ALDH1A1 (0.40) | GAAMGLLNOTUMALDH1A1MAPT | |
| SCHEMBL30147910 | 0.71 | ALDH1A1 (0.40) | GAAMGLLNOTUMALDH1A1MAPT | |
| SCHEMBL28494012 | 0.71 | MYC (0.46) | KDM4EMGLLNOTUMALDH1A1HSD17B10 | |
| SCHEMBL6406762 | 0.71 | SIGMAR1 (0.39) | GAANOTUMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | KDM4E 900/4885GAA 2720/4885CARM1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.